Lipid management with statins in type 2 diabetes mellitus

Annals of Pharmacotherapy

Volumn 39, Issue 10, 2005, Pages 1714-1719

  Irons, Brian K ^a   Kroon, Lisa A ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diabetes; Lipids; Statins

Indexed keywords

ATORVASTATIN; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; PRAVASTATIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; ENZYME BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LOW DRUG DOSE; MEDLINE; MORBIDITY; MYOPATHY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SYSTEMATIC REVIEW;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID METABOLISM; MEDLINE; TREATMENT OUTCOME;

EID: 25844447106     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G069     Document Type: Review

References (19)

1. American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003;26:917-32.
2. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
4. Pyorala K, Pedersen T, Kjekshus J, Faergeman O, Olsson A, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20: 614-20.
5. Keech A, Colquhoun D, Best J, Kirby A, Simes J, Hunt D, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID Trial. Diabetes Care 2003;26:2713-21.
6. Goldberg R, Mellies M, Sacks F, Moye L, Howard B, Howard W, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial. Circulation 1998;98:2513-9.
7. Shepherd J, Cobbe S, Ford I, Isles C, Lorimer A, MacFarlane P, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
8. Downs J, Clearfield M, Weis S, Whitney E, Shapiro D, Beere P, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
9. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-8.
10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
11. Colhoun H, Betteridge D, Durrington P, Hitman G, Neu H, Livingstone S. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
12. Grundy S, Cleeman J, Merz N, Brewer B, Clark L, Hunninghake D, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-39.
13. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005;28(suppl 1):S4-36.
14. Sever P, Dahlöf B, Poulter N, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
15. Cannon C, Braunwald E, McCabe C, Rader D, Rouleau J, Belder R. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
16. de Lemos J, Blazing M, Wiviott S, Lewis E, Fox K, White H, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to 2 trial. JAMA 2004;292:1307-16.
17. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
18. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 1998;21(suppl 1):S36-9.
19. LaRosa J, Grundy S, Waters D, Shear C, Barter P, Fruchart J, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.